![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Molecular Pharmacogenetics Laboratory (S.K., Q.H., A.A.-R., L.M.H., M.H.C.) and Clinical Pharmacology Laboratory (L.L.v.M., D.J.G.), Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts
The objective of this study was to use recombinant enzymes and human liver microsomes (HLMs) to comprehensively evaluate the functional impact of the three most common nonsynonymous polymorphisms (S7A, T181A, and R184S) identified in the human UDP glucuronosyltransferase (UGT) 1A6 gene. In addition to the known allozymes, other possible amino acid variants were expressed in human embryonic kidney (HEK)293 cells to enable structure-function analysis. Initial studies using different substrates (serotonin, 5-hydroxytryptophol, 4-nitrophenol, acetaminophen, and valproic acid) showed similar results with 2-fold higher glucuronidation by UGT1A6*2 (S7A/T181A/R184S) compared with UGT1A6*1 (reference), and intermediate activities for other variants. Enzyme kinetic analyses with the UGT1A6-specific substrate (serotonin) showed 50% lower Km values for all R184S variants and 2-fold higher Vmax values for both S7A/T181A variants compared with UGT1A6*1. Furthermore, intrinsic clearance (Vmax/Km) values were highest for the UGT1A6*2 allozyme (2.3-fold over UGT1A6*1), resulting from additive effects of higher enzyme affinity and activity. As expected, Km values of *1/*1 genotyped HLMs (5.4 ± 0.2 mM) were similar to recombinant UGT1A6*1 (5.8 ± 0.6 mM). Conversely, *2/*2 HLMs showed higher Km values (7.0 ± 0.3 mM) rather than the lower Km values displayed by recombinant UGT1A6*2 (3.6 ± 0.3 mM), suggesting that this allozyme may display different enzyme kinetic behavior in HLMs compared with HEK293 cells. At best, these polymorphisms were predicted to account for 15 to 20% of the observed 13-fold variability in glucuronidation of UGT1A6 substrates by HLMs, indicating that there are likely other genetic or environmental factors responsible for the majority of this variation.
Address correspondence to: Dr. Michael H. Court, Molecular Pharmacogenetics Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University, 136 Harrison Ave., Boston, MA 02111. E-mail: michael.court{at}tufts.edu.
This article has been cited by other articles:
|
|
 |
|
  P. Sun, J. Qian, Z.-b. Zhang, J.-x. Wan, F. Wu, X.-p. Jin, W.-w. Fan, D.-r. Lu, N.-q. Zhao, D. C. Christiani, et al. Polymorphisms in phase I and phase II metabolism genes and risk of chronic benzene poisoning in a Chinese occupational population Carcinogenesis, December 1, 2008; 29(12): 2325 - 2329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nguyen, J. A. Bonzo, S. Chen, S. Chouinard, M. J. Kelner, G. Hardiman, A. Belanger, and R. H. Tukey Disruption of the Ugt1 Locus in Mice Resembles Human Crigler-Najjar Type I Disease J. Biol. Chem., March 21, 2008; 283(12): 7901 - 7911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hubner, K. R. Muir, J.-F. Liu, R. F.A. Logan, M. Grainge, N. Armitage, V. Shepherd, S. Popat, R. S. Houlston, and the United Kingdom Colorectal Adenoma Prevention C Genetic Variants of UGT1A6 Influence Risk of Colorectal Adenoma Recurrence. Clin. Cancer Res., November 1, 2006; 12(21): 6585 - 6589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chen, D. Beaton, N. Nguyen, K. Senekeo-Effenberger, E. Brace-Sinnokrak, U. Argikar, R. P. Remmel, J. Trottier, O. Barbier, J. K. Ritter, et al. Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus J. Biol. Chem., November 11, 2005; 280(45): 37547 - 37557. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
